WHAT THIS PAPER ADDS Currently, there are very few reports of the complications of venous stent placement. This article reports the authors' experience and provides guidance and recommendations for clinicians on how to treat these complications and how to follow up on patients.
INTRODUCTION
During the last two decades endovenous recanalization, by percutaneous transluminal angioplasty (PTA) and stenting, in chronic deep venous obstructive disease has quickly gained in popularity. Many authors have shown excellent clinical success rates. 1e3 Because of this, and as stenting seems to be the only treatment aimed at resolving the underlying pathology in post-thrombotic syndrome (PTS) and iliac vein compression syndromes, it has been implemented in many expert venous centers worldwide as a first line treatment. Complication rates have been shown to be low, with generally no clinically relevant pulmonary emboli and no procedure related mortality. 3e5 The most important complication is acute re-occlusion of the stented venous segment, with or without thrombus propagation into proximal or distal vein tracts. This occurs in 20e30% of cases, even when adequate anticoagulation regimens are used. 4 In cases of stent re-occlusion return of signs and symptoms of venous disease can be expected, and in some cases worsening of complaints compared with the prerecanalization state. An important step in preventing reocclusion is to guarantee adequate in-and outflow for the stents. Inflow problems can arise when veins caudal to the stented segments are also involved in the postthrombotic process, most notably the femoral and deep femoral vein, as flow volume in such cases might not be sufficient to maintain patency. Outflow problems arise when venous tracts cephalad to the stents are (partly) obstructed owing to endoluminal pathology or external compression. Furthermore, in-stent problems, for example residual compression by overlying arteries, stenosis, kinking, or fractures, are also thought to lead to a higher loss of patency. Prevention by extending stents cephalad or caudal into a healthy vein tract and using stents that withstand the pressure from overlying structures such as arteries and do not kink are therefore very important. 6 Adequate antithrombotic therapy is also important in preventing rethrombosis.
In cases where re-occlusion occurs, removal of as much of the thrombus load as quickly as possible is generally thought necessary. 7 One possible option is to remove the thrombus by means of pharmaco-mechanical thrombolysis. Ultrasound accelerated catheter directed thrombolysis (UACDT) is used for acute occlusions in the arterial system, deep vein thrombosis (DVT), and pulmonary embolism. The literature shows good safety and feasibility for UACDT for these indications. Possible advantages of UACDT over the use of a normal thrombolysis catheter are shortened treatment duration and smaller volumes of thrombolytic used, reducing the risk of (major) bleeding. 12 In the literature, when there is adequate patient selection, the chance of achieving technical success is around 90%, together with a minimal risk of bleeding. 13 In this study the experience of treating in-stent thrombosis with UACDT in patients referred to a tertiary center is reported. Furthermore, the pitfalls that have been encountered in these cases are described, and recommendations are made on how to follow up patients after venous stenting.
METHODS

Population
From October 2009 to July 2014 all patients treated for venous stent occlusion by UACDT were eligible for inclusion in this retrospective analysis. All patients were evaluated for bleeding risk. Indication for primary stent placement was either chronic venous obstructive disease or persistent vein compression in patients with acute ilio-femoral DVT during thrombolytic therapy. Time between stent placement and occlusion was assessed and patients were divided into two groups (within 6 months of stent placement, and longer than 6 months after stent placement). Occlusion side was noted and, if available, thrombophilia status was reported.
No additional testing for thrombophilia factors was performed. Duration of occlusion and suspected clot age were assessed from patient complaints and findings on duplex ultrasonography (DUS).
14 Patient complaints were assessed and used as the criterion to categorize patients into two groups: complaints for 21 days, and >21 days. The last patent duplex scan was taken as a reference value for assessment of clot age. Stent obstruction was diagnosed using DUS with normal B-mode settings, power flow, e-flow, conventional color, and pulse wave Doppler to assess flow in the stent tract. At least one of the available modalities or combinations was used. The venous tract was assessed in both transverse and longitudinal planes. In order to visualize flow in the stented ilio-caval tract a number of flow augmenting maneuvers were performed, such as inspiration and expiration, dorsiflexion of the foot, and gluteal muscle contraction.
Before recanalization and catheter placement, venography was routinely performed to confirm the diagnosis of stent obstruction.
Dutch law allows for retrospective analysis of patient data without specific approval of an ethical committee.
Intervention
The interventional radiologist placed the UACDT catheter under venographic control. The EKOS Endowave Peripheral Lysis System (BTG International Ltd, London, UK) consists of a multilumen infusion catheter with removable, coaxial ultrasound (US) cores and a control unit that simultaneously delivers high-frequency (2.2 MHz), low energy (0.45 W) US energy and thrombolytic drug into the thrombus. All patients received UACDT with the EKOS Endowave system. Urokinase (Medacinase, Lamepro, the Netherlands) was used as the thrombolytic agent in all cases. Urokinase was administered at 100,000 units/hour after a single bolus of 250,000 units at the start of treatment. In cases of bilateral occlusion, two catheters were inserted and the drug dosage was evenly divided over the two catheters, each with their own EKOS machine. During thrombolysis fibrinogen, hemoglobin, activated partial thromboplastin time (APTT), prothrombin time standardized to international normalized ratio (INR), thrombocytes, and D-dimer levels were routinely monitored. During active thrombolysis, anticoagulant treatment was substituted by intravenous unfractionated heparin guided by APTT (between 40 and 60 seconds or 1.2e1.7-fold the reference value of 34 seconds). At the same time, patients were fitted with intermittent pneumatic compression sleeves. Inferior vena cava filters are not used routinely at the authors' hospital. None of the patients received a caval filter. After thrombolysis, patients either resumed or started oral anticoagulation for at least 6 months or, if indicated, for life (recurrent DVT). Adequate anticoagulation was achieved with either Coumadin (Bristol-Myers Squibb, New York, NY, USA) with an INR between 2.5 and 3.5, according to the standards of the Dutch Federation of Thrombosis Services, or rivaroxaban 20 mg once daily. The choice of anticoagulant agent was based on patient preference. Compression stockings were routinely offered to patients and worn based on the preference of the patient. Mobilization was encouraged.
Assessment of recanalization
Phlebography was performed daily to monitor thrombolysis progression and to evaluate obstructions in the venous outflow tract. Duration of thrombolysis was determined by assessment of phlebographic imaging and the point where >90% lysis of the clot had been achieved. 15 Because of bridging towards additional treatment, thrombolysis was continued in a number of cases. Determination of the cause of the stent thrombosis by means of phlebography from multiple angles was attempted. In some cases cone beam computed tomography was used to create a three dimensional reconstruction of the stent tract. If the reason for thrombosis of the tract was identified, adequate measures were taken to resolve the problem and prevent future rethrombosis. Objective identification of the underlying cause of stent thrombosis was only possible in patients with successful thrombolysis.
Additional procedures
After successful UACDT procedures, patients received additional interventions if indicated. Additional procedures were performed as soon as possible after successful thrombolysis. Additional procedures such as PTA with or without re-stenting were performed by the interventional radiologist. Surgical procedures to increase inflow such as construction of an AV-fistula between the common femoral vein and artery or endophlebectomy were performed by the vascular surgeon. Self expandable stents for stenting of underlying obstructions were used (sinus-XL and sinusVenous [Optimed, Ettingen, Germany] and Zilver vena [Cook, Bloomington, IN, USA]). Various diameters and lengths of stent were used ranging from 12 to 26 mm in diameter and from 60 to 150 mm in length. Stent sizes were determined by multiplanar venography.
Complications
Complications following thrombolysis and follow up were categorized into groups. These included bleeding complications, pulmonary embolism (PE), recurrent thrombosis, infections, and others. Bleeding was classified as major if it was overt, with a fall in hemoglobin of !2 g/dL, or when hemorrhage led to transfusion of two units of packed red blood cells or whole blood. Bleeding situated in a critical organ (intracranial, retroperitoneal or pericardial) or if it contributed to death was also defined as major bleeding. Bleeding was classified as minor if it was situated near the catheter insertion site.
Follow up
Standardized follow up was performed. Patients returned at 2 weeks, 6 weeks, 3 months, 6 months, 1 year, and annually thereafter. If the patient experienced complaints, follow up was performed at the earliest convenience, usually the same or next day. During follow up patency of the stent tract was assessed using DUS. A dedicated sonographer performed DUS. Recurrence, re-treatment, PE, and other complications were recorded.
Routine follow up after stenting was standardized in this manner: the day after stenting, patients were checked with DUS to ensure patency of the tract prior to discharge. At 2 weeks, 6 weeks, 3 months, and 6 months after stenting the patients were seen with clinical follow up and routine DUS examination. The complete stented tract was visualized in every patient. Apparent thrombosis and/or lack of flow in the stented tract were used to determine patency.
RESULTS
Patients
A total of 19 legs in 18 patients were treated with UACDT for venous stent thrombosis. The majority of patients were male. At the time of thrombolysis the average age was 43 years. In 33% of cases the initial indication for stent placement was an underlying stenosis after acute iliofemoral DVT treatment with UACDT. The remaining 67% received PTA and stenting as a treatment for chronic deep venous obstruction and subsequent complaints. Most (67%) stents were placed in the left iliac tract. Most (83% of patients) stent occlusions occurred within 6 months of their initial placement. In 13 (72%) patients the duration of complaints was assessed. In the other cases it was not possible to make an assessment of duration of complaints, either because of their vagueness or absence. Eleven patients were assessed as having acute thrombosis (<21 days, according to the reporting standards in venous disease). Patient characteristics are summarized in Table 1 .
Before the UACDT to treat the in-stent re-thrombosis, patients had received a median of three (range 1e13) stents in 1e3 stenting sessions. This was done on the left side in 13, on the right side in one, and bilaterally in three cases; one patient only had stents placed in the inferior vena cava. In all patients Nitinol self expandable stents were used (sinus XL, sinus repo-visual, sinus Venous); in two cases these were combined with WALLSTENTs (Boston Scientific, Marlborough, MA, USA), and in one case with balloon expandable stents (Andramed, Reutlingen, Germany). Table 1 shows the baseline characteristics of the patients.
Treatment results and additional procedures
All patients underwent UACDT with the EKOS catheter.
Catheter placement was successful in all cases. In 11/18 patency was successfully restored. This resulted in a technical success rate of 61%. All patients with failed thrombolysis had an unknown or estimated clot age of >21 days and last patent duplex >21 days previously. Median lysis time of successfully lysed cases was 19 hours (range 11e 101 hours). In five cases additional stenting was performed and an arteriovenous (AV) fistula created to treat an underlying cause such as a stenotic lesion not treated previously. Figs. 1 and 2 show pre-and post-thrombolysis results. Furthermore, stent related occlusions and insufficient inflow in the stent tract were encountered. In two cases additional stenting was performed, and in one patient inflow to the stent tract was secured by creation of an AV fistula. In total, 8/11 (73%) patients needed ancillary interventions after successful thrombolysis. In all cases of UACDT the underlying cause of re-thrombosis was identified. These were suboptimal positioning, failure due to stent characteristics (kinking of stents and stent fracture), insufficient inflow, or inadequate anticoagulation. Fig. 3 shows an example of stent fracture in the venous system. Most occlusions encountered were related to stent failure and suboptimal positioning. Table 2 shows the treatment results. Table 3 shows the time between last patent duplex and occlusion, suspected clot age, and suspected reason for re-occlusion.
Complications
Six patients experienced adverse events. During UACDT two had a fall in hemoglobin without a bleeding focus, which necessitated transfusion. One patient had minor bleeding at the catheter insertion site, which was solved by manual compression. One patient experienced heparin induced thrombocytopenia. Heparin was switched for intravenous argatroban for the further duration of UACDT. One patient complained of blepharoedema and urticaria, which was recognized as an allergic reaction to the iodine contrast used for venography unrelated to thrombolytic therapy. One patient had fever with positive blood cultures during thrombolysis. In this patient thrombolysis was stopped and treatment with antibiotics started. None of the patients experienced multiple complications. There were no clinically relevant pulmonary emboli or treatment related mortality. Table 4 gives an overview of all complications encountered during UACDT.
Follow up
Of the successfully lysed patients (n ¼ 11), eight remained patent, a primary patency of 73%. Seven patients experienced complete relief of complaints and two had partial relief. One patient's complaints were not relieved. In one case, due to stent related problems, there was an immediate re-occlusion the day after successful lysis. Table 5 shows the follow up data for the successfully lysed patients.
DISCUSSION
With the growing number of effective thrombolytic treatments in acute ilio-femoral DVT, it is expected that an increasing number of patients will also be stented for residual stenotic lesions. Some reports show that >50% of patients are stented after thrombolysis. 16 At the same time,
there are also more interventions performed in patients with PTS due to extensive chronic occlusions in the ilio-caval tract. As both of these procedures gain in popularity, it can be expected that more venous stenting related complications will be encountered. In this study, re-occlusion was identified to be the most frequent and clinically important complication after venous stenting, and, to the authors' knowledge, this is the first study to focus specifically on how to treat this important complication. Earlier studies also highlighted stent occlusions to be an important complication after venous stenting. 4, 5, 17 A technically successful recanalization of occluded stents in the venous system of 61% and a primary patency of 73% after a median follow up of 12 months is reported here. In all cases it was possible to get a wire across the occluded segment. In all cases the intention was to treat stent occlusion with a suggested thrombus age of <21 days based on complaints or homogenicity on DUS. In this series, thrombolysis within 21 days seemed to result in more success than interventions performed at a later stage. Although there is one report on successful interventions in the chronic DVT phase, 18 it was not possible to reproduce these findings in the current study. It is important to assess the time of onset of the thrombosis accurately. It was found 
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Re-stenting after successful UACDT (n ¼ 11) 7 (64) Other additional interventions after successful UACDT (n ¼ 11)
Arteriovenous fistula 6 (55) Note. Values are given as n (%) unless otherwise stated.
in the current study that patient reported duration of complaints was not useful in determining thrombus age and therefore the success rate of the thrombolysis was not predictable. Other techniques, such as magnetic resonance venography, DUS elastography, or intravascular ultrasound, might prove more useful in determining thrombus age, better predict outcome, and be used for patient selection. 19 Regarding the specific usefulness of UACDT in regaining patency, a median time to lysis of 90% of the thrombus of 19 hours was found in the current study, which is fairly quick. However, in some cases lysis treatment was continued until the necessary additional procedures could be performed.
Two rare complications were encountered: heparin induced thrombocytopenia and contrast allergy. There were two major cases of hemorrhage requiring transfusion. Other complications involved catheter insertion site bleeding, which were very minor; therefore, it may be concluded that UACDT is a safe procedure.
Many stent related flow complications result in reocclusion of the venous tract. Occlusion of the stent tract nullifies the progress gained by the initial treatment. When encountered at an early stage, the thrombosed stent tract can be cleared by thrombolysis. 4 Patency can be regained and, most importantly, the underlying cause of occlusion can be identified or should be identified during the procedure. UACDT is one of the available options for regaining patency. Other clot removal therapies can also be used for this purpose. 20 In all cases of successful thrombolysis the underlying cause of the occlusion was identified. Also, in the group that did not have successful thrombolysis, stent related causes for occlusion were identified. In total, in 15/18 cases, stent related failures such as kinking, fracture, and continuous compression of the stents were encountered. These stent related problems are potentially due to the stent characteristics. The stents used in this study are primarily designed for arterial use. With new, dedicated venous stents future stent related occlusions are expected to be prevented. Ideally, dedicated venous stents with high flexibility, high radial force, and large diameters are used in the venous system. 21 A number of dedicated venous stents are now commercially available.
Most of the occlusions occurred within 6 months of the initial stenting. Strict follow up of patients is therefore paramount. The frequent follow ups allowed for timely interventions with UACDT to prevent re-occlusion. At the 6 month visit continuation of anticoagulation was evaluated based on stent configuration, patient risk factors, and patient preference. Thrombocyte aggregation inhibitors were not routinely prescribed following cessation of Coumadin, although they might be of influence. If at any point between follow up visits patients experienced complaints, they were seen at the earliest convenience. After 6 months, follow up visits were planned at 1 year and annually thereafter, depending on patient preference.
The most difficult problem encountered in this study involved patients with poor inflow due to extensive chronic venous occlusive disease with scarring in both major inflow vessels (i.e., femoral and deep femoral vein.). Currently, there are no reported successful treatments available for these veins. Endophlebectomy with or without AV fistula has been described in the literature as a treatment option.
22e24 Stenting might be a possibility for these veins however, the currently available options are not suitable for placement in the femoral or deep femoral tract. To ensure adequate inflow, the creation of a temporary AV fistula, with or without an endophlebectomy of the common femoral vein, is currently relied upon. 25 Further research is needed to improve care in these cases.
One of the drawbacks of this study is its retrospective nature. The expected number of cases per center per year is expected to be very low, which makes it challenging to complete a prospective study. Optimal registration of patient data and pooling of results from retrospective studies could improve patient care considerably. Therefore, other centers should be encouraged to report their experience regarding stent thrombosis and treatment.
CONCLUSION
Treatment with UACDT of occluded stent tracts is feasible and effective. Recanalization of the stent tract can be achieved in some cases with recent thrombosis <21 days. Additional interventions were frequently necessary after successful UACDT treatment. Most stent occlusions were caused by stent related problems.
